

Atty. Docket No.  
ALZ5015 USA R1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Samuel Zalipsky et al.

Serial No.: To be assigned

Filed: Filed herewith

For: METHOD TO REDUCE LIPOSOME-  
INDUCED COMPLEMENT  
ACTIVATION

Group Art Unit: to be assigned

Examiner: to be assigned

**INFORMATION DISCLOSURE  
STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing

date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

Copies of references listed on the attached Form PTO-1449 are enclosed herewith  
EXCEPT THAT:

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750.

Respectfully submitted,

Judy M. Mohr 2/26/04  
Attorney for Applicants  
Judy M. Mohr Reg. No.: 38,563  
Tel. No.: 650-564-2867  
Fax. No. 650-564-2195

ALZA CORPORATION  
c/o Johnson & Johnson  
One Johnson & Johnson Plaza, WH3221  
New Brunswick, NJ 08933  
Customer No.: 27777

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A-PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 1 of 1	<b>Application Number</b>	Not yet assigned
	<b>Filing Date</b>	Filed Herewith
	<b>First Named Inventor</b>	Samuel ZALIPSKY et al.
	<b>Group Art Unit</b>	Not yet assigned
	<b>Examiner Name</b>	Not yet assigned
	<b>Attorney Docket Number</b>	ALZ5015 R1 / ARC 3222

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	6,586,001	B1	Zalipsky	07/01/2003	
	AB	6,015,679		Kubotsu et al.	01/18/2000	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T <sup>2</sup>
-------------------------	--------------------------	--	----------------

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

	AC	Janos Szebeni, et al., "Role of Complement Activation In Hypersensitivity Reactions To Doxil and Hynic PEG Liposomes: Experimental and Clinical Studies"; <u>Journal of Liposome Research</u> , 12(1&2), Pages 165-172 (2002).	
	AD	Amanda J. Bradley, et al. "Inhibition of Liposome-Induced Complement Activation by Incorporated Poly(Ethylene Glycol)-Lipids"; <u>Archives of Biochemistry and Biophysics</u> , Vol. 357, No. 2, September 15, pp 185-194 (1998). Article No. BB980798.	
	AE	Janos Szebeni, et al., "Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction"; <u>Am J. Physiol Heart Circ Physiol</u> . 279: (10 pages) H1319-H1328 ( 2000).	
	AF	Peter Laverman, et al., "In Vivo Applications of PEG Liposomes: Unexpected Observations"; <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> , 18(6): 551-566 (2001).	
	AG	Janos Szebeni, et al., "Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in Pigs"; <u>Liposome-Induced Cardiopulmonary Changes in Pigs</u> , Pages 2302 - 2309 (May 4, 1999).	
	AH	Janos Szebeni, "The Interaction of Liposomes with the Complement System"; <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> , 15(1): 57-88 (1998).	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.